Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
130 hedge funds and large institutions have $415M invested in Achillion Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 19 closing their positions.
425% more call options, than puts
Call options by funds: $4.31M | Put options by funds: $821K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1% more capital invested
Capital invested by funds: $411M → $415M (+$4.18M)
5% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 42
7% less funds holding
Funds holding: 140 → 130 (-10)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$40.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$3.58M |
| 3 |
Millennium Management
New York
|
+$3.28M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.68M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$3.34M |
| 2 |
Goldman Sachs
New York
|
-$3.02M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
-$2.24M |
| 4 |
Morgan Stanley
New York
|
-$1.98M |
| 5 |
Citigroup
New York
|
-$1.92M |
ACHN Hedge Fund Activity: Q1 2017 in Review
130 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2017, worth a combined $415M — up 1% from $411M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ACHN and 16 opened new positions — a net loss of 3 holders — while 42 trimmed existing stakes and 40 added.
The largest buyer was BlackRock, adding an estimated $40.9M. The largest seller was State Street, cutting an estimated $3.34M.
- 130 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2017, down from 140 in Q4 2016.
- Funds reported $415M of Achillion Pharmaceuticals stock for Q1 2017, up 1% quarter-over-quarter.
- 16 funds opened new Achillion Pharmaceuticals positions in Q1 2017 and 19 closed out, a net change of -3 holders.
- The largest Achillion Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $40.9M added.
- The largest Achillion Pharmaceuticals seller in Q1 2017 was State Street, an estimated $3.34M sold.
Based on aggregated 13F filings for Q1 2017.